We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · December 04, 2021

Efficacy and Safety of Dapagliflozin in HFrEF According to NT-proBNP

Circulation: Heart Failure

 

Additional Info

Disclosure statements are available on the authors' profiles:

Circulation: Heart Failure
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Circ Heart Fail 2021 Nov 22;[EPub Ahead of Print], JH Butt, C Adamson, KF Docherty, RA de Boer, MC Petrie, SE Inzucchi, MN Kosiborod, A Maria Langkilde, D Lindholm, FA Martinez, O Bengtsson, M Schou, E O'Meara, P Ponikowski, MS Sabatine, M Sjöstrand, SD Solomon, PS Jhund, JJV McMurray, L Køber

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading